JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB280943

Recombinant human PD-L1 protein (Active)

Recombinant human PD-L1 protein (Active)

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant human PD-L1 protein (Active) is a Human Fragment protein in the 19 to 238 aa range with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, Functional studies, ELISA, mass spectrometry and HPLC. The predicted molecular weight of ab2809432 protein is 25.3 kDa.

- Save time and ensure accurate results - use our PD-L1 protein as a control
- Optimal protein bioactivity, stability and reproducibility
- Available in different sizes to fit your experimental needs

別名を表示する

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

5 Images
Sandwich ELISA - Recombinant human PD-L1 protein (Active) (AB280943)
  • sELISA

Lab

Sandwich ELISA - Recombinant human PD-L1 protein (Active) (AB280943)

Sandwich ELISA - Recombinant human PD-L1 protein standard curve.

Background subtracted standard curve using Human/Monkey PD-L1 [28-8] Antibody Pair - BSA and Azide free (ab253485) and Recombinant human PD-L1 protein (Active) (ab280943) in sandwich ELISA. The ELISA was performed using the components of the corresponding SimpleStep® kit, which uses the same antibody pair with a different formulation and format.

Functional Studies - Recombinant human PD-L1 protein (Active) (AB280943)
  • FuncS

Supplier Data

Functional Studies - Recombinant human PD-L1 protein (Active) (AB280943)

Functional analysis of an280943.

Fully biologically active measured by its ability to inhibit anti-CD3 and anti-CD8 antibody induced T-cell expansion. ED50 for this effect is ≤500 ng/mL with a specific activity of 0.2 x 104 units/mg.

Cell based assay testing is performed on the first lot of protein only and is provided as a reference for protein activity; subsequent lots of protein must pass all biophysical quality control parameters that meet the same parameters as the first lot.

Lot : GR3381126-2

Mass Spectrometry - Recombinant human PD-L1 protein (Active) (AB280943)
  • Mass Spec

Supplier Data

Mass Spectrometry - Recombinant human PD-L1 protein (Active) (AB280943)

Mass determination by ESI-TOF.

Predicted MW is 25250.68 Da (+/- 10 Da by ESI-TOF). Observed MW is 25097.90 Da. M-100 due to loss of C-terminal arginine.

HPLC - Recombinant human PD-L1 protein (Active) (AB280943)
  • HPLC

Supplier Data

HPLC - Recombinant human PD-L1 protein (Active) (AB280943)

HPLC analysis of ab280943.

SDS-PAGE - Recombinant human PD-L1 protein (Active) (AB280943)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant human PD-L1 protein (Active) (AB280943)

SDS-PAGE analysis of ab280943.

Key facts

精製度

>95% SDS-PAGE

エンドトキシンレベル

<0.005 EU/µg

発現系

HEK 293 cells

タグ

Tag free

アプリケーション

SDS-PAGE, HPLC, Mass Spec, FuncS, sELISA

applications

生物活性

Yes

生物学的活性

Fully biologically active measured by its ability to inhibit anti-CD3 and anti-CD8 antibody induced T-cell expansion. ED50 for this effect is ≤500 ng/mL with a specific activity of 0.2 x 104 units/mg.

アクセッション番号

Q9NZQ7

アニマルフリー

Yes

キャリアフリー

No

種

Human

再構成

Reconstitute in PBS

バッファー組成

pH: 7.4 Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "HPLC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

製品の詳細

Ensure the validity of your result using our recombinant human PD-L1 protein ab280943 as a control.

The ab280943 PD-L1 protein is sourced from HEK293 cells and can be used as a positive control in SDS-PAGE, mass spectrometry and HPLC. Analyze your PD-L1 ELISA data using the ab280943 protein to generate and plot a standard curve.

Check out our protein gel staining guide for SDS-PAGE here

Check out our ELISA protocol for more information here.

Premium Bioactive Protein range

The ab280943 PD-L1 protein is part of the premium bioactive protein range which are ideal for preclinical cell culture and functional studies. These recombinant proteins are of the highest activity, purity, and consistency, meeting rigorous biophysical characterization.

More premium bioactive proteins can be found here
style
left-column

配列情報

[{"sequence":"FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNER","proteinLength":"Fragment","predictedMolecularWeight":"25.25 kDa","actualMolecularWeight":"25.1 kDa","aminoAcidEnd":238,"aminoAcidStart":19,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q9NZQ7","tags":[]}]
style
left-column

出荷温度及び保存条件

出荷温度
Ambient - Can Ship with Ice
短期保存温度
Ambient
長期保存温度
Ambient
True
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column

製品の性状

製品の状態

Lyophilized

補足情報

=95% by HPLC

style
left-column

一般的な情報

機能

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

配列の類似性

Belongs to the immunoglobulin superfamily. BTN/MOG family.

翻訳後修飾

Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by USP22; leading to stabilization (PubMed:31399419).

style
left-column

製品プロトコール

style
left-column

ターゲットの情報

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
See full target information CD274
style
left-column

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Translational oncology 52:102248 PubMed39709718

2024

Response Gene to Complement 32 is associated with poor patient survival and an inflamed tumor-immune microenvironment in clear cell renal cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Lingling Li,Xiaocui Bu,Shuhui Wang,Yan Liu,Chongdao Chen,Wei Zhang,Peng Zhao
View all publications
style
left-column
style
left-column
style
right-column

組合せ製品

Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Proteins & Peptides

AB280753

Recombinant Human PD1 protein

Mass Spectrometry - Recombinant Human PD1 protein (AB280753)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB52587

Anti-PD1 antibody [NAT105]

BOND RX™ Validated|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

  • 5
  • 9

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com